In conclusion, in this trial of prospectively enrolled patients with SDH-deficient GISTs, olverembatinib was well tolerated, the CBR was more than 80%, and the estimated median PFS was significantly prolonged, indicating a potential benefit of this treatment and providing a benchmark for future studies in this rare subtype of GIST. The gene discussed is SDHB; the disease is gastrointestinal stromal tumor.